No Definite Link Between Yoga, Quality of Life in Patients With Colorectal Cancer
the Cancer Therapy Advisor take:
Given the trial’s high attrition rate and low intervention adherence, no definite conclusions can be made between yoga and the health-related quality of life in patients with colorectal cancer, according to an article published online in the journal Psycho-Oncology.
Participants in this study included 54 patients (mean age 68.3 ± 9.7 years) who were randomly assigned to a 10-week yoga intervention (90 minutes once weekly; mean attendance 5.3 ± 4.0 yoga classes) or a waitlist control group. Twenty-seven patients were randomized to both the yoga and control group (attrition rate 22.2% and 18.5%, respectively).
Results showed no significant differences in the Functional Assessment of Cancer Therapy—Colorectal (FACT-C) total score between the two groups, which measured disease-specific quality of life.
However, differences were observed between the two groups’ emotional well-being at week 22 (∆ = 1.59; 95% CI: 0.27, 2.90; P= 0.019), sleep disturbances at week 22 (∆ = −1.08; 95% CI: −2.13, −0.03; P=0.043), anxiety at week 10 (∆ = −1.14; 95% CI: −2.20, −0.09; P=0.043), and depression at week 10 (∆ = −1.34; 95% CI: −2.61, −0.8; P=0.038).
Furthermore, no serious adverse events were observed in the yoga intervention cohort, while liver metastases occurred in one patient in the control group.
No definite conclusions can be made between yoga and the health-related quality of life in patients with colorectal cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Plastics and Cancer
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer